CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The standard or usual treatment for this disease is to undergo chemotherapy to slow the
spread of disease and relieve some symptoms of cancer. One of the standard types of
chemotherapy is a drug called paclitaxel (Taxol) given in a low dose every week for three out
of four weeks.
CFI-402257 is a new type of drug for breast cancer. Laboratory tests show that it may help
slow the growth of breast cancer. This drug has been shown to shrink tumours in animals.
CFI-402257 has been studied in a few people and appears well tolerated with little side
effects. CFI-402257 seems promising but it is not clear if it can offer better results when
given with paclitaxel compared to paclitaxel alone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Canadian Breast Cancer Foundation Ontario Institute for Cancer Research Stand Up To Cancer